Huntington
Beyond's analysis on Huntington
- — Payments technology accelerates Huntington’s merger integration
- — UniQure's pursuit of FDA approval for a Huntington's disease gene therapy underscores the high-stakes regulatory journey for rare-disease biotech innovators
Recent news mentioning Huntington
- — Skyhawk Therapeutics gibt die endgültigen Ergebnisse nach 15 Monaten aus der klinischen Phase-1/2-Studie mit SKY-0515 bei Patienten mit Huntington-Krankheit bekannt
- — Huntington Bancshares Incorporated Increases its Prime Rate to 7.00 Percent
- — Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients
- — Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients
- — Huntington Bank to Relocate Historic Downtown Columbus Branch to New Storefront at Broad and High
- — Huntington sues 24 R&R companies over more than $12M in debt
- — Huntington Bancshares Incorporated to Present at the 2026 Barclays Global Financial Conference
- — Huntington elevates Standridge to president
- — Huntington Bank Chairman Gary Torgow Joins The Henry Ford Board of Trustees
- — Huntington Insurance Named a 2026 Best Place to Work in Insurance by Business Insurance Magazine
- — Huntington Bank Opens First Branch in Mount Pleasant
- — Are Wall Street Analysts Bullish on Huntington Ingalls Stock?